Stevens - Johnson syndrome due to nevirapine.

Abstract

A 25-year-old HIV-infected woman participating in a study of the effects of hormonal contraception on HIV disease progression was started on antiretroviral therapy-Combivir & Nevirapine (NVP) on May 27, 2004. NVP was 200mg daily initially for two weeks to be increased to 200mg bid thereafter. On day twelve, she presented with a mild skin rash on the trunk, purulent conjunctivitis, pharyngitis and fever. She was treated symptomatically and sent home. The following day she returned with a generalized erythematous eruption. She was admitted to JCRC (Joint Clinical and Research Centre) on June 14 and was diagnosed with Stevens - Johnson syndrome (SJS). Antiretroviral therapy was stopped. By July 05, 2004, she had improved and was discharged. After recovery she was restarted on Combivir and Efavirenz and is subsequently doing well on this regimen.

• Authors: G K Namayanja, J M Nankya, J K Byamugisha, F N Ssali, C M Kityo, S D Rwambuya, R D Mugerwa, F A Mmiro, C S Morrison, R A Salata
• Journal: African health sciences (Afr Health Sci) Vol. 5 Issue 4 Pg. 338-40 (Dec 2005) ISSN: 1729-0503 [Electronic] Uganda
• PMID: 16615847 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-HIV Agents
• Nevirapine

Topics

• Adult
• Anti-HIV Agents (adverse effects)
• Female
• Humans
• Nevirapine (administration & dosage, adverse effects)
• Stevens-Johnson Syndrome (chemically induced, physiopathology)
• Treatment Outcome